This page shows the latest Erelzi news and features for those working in and with pharma, biotech and healthcare.
Global sales of biopharmaceuticals grew 27%, according to the third quarter report, which was driven by strong double-digit growth in Europe from Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi (etanercept).
Sandoz’s sales in the second quarter of 2019 climbed 3% to $2.4bn, with double-digit gains in Europe for its trio of biosimilars rixathon (rituximab), hyrimoz (adalimumab) and erelzi ... competition. Despite Sandoz gaining approval in 2016for erelzi,
The Novartis subsidiary was looking to the case in the District Court of New Jersey to clear some of the barriers to the commercial launch of the biosimilar, called Erelzi ... We will appeal this decision, and look forward to presenting our case to the
Vas Narasimhan. In the second quarter Sandoz sales were up 3% to $2.4bn, with double-digit gains in Europe for its trio of biosimilars - Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi
Despite discussions of a possible sell-off, Sandoz’s biosimilars division is performing well, with double digit growth in Europe thanks to products such as Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi
Erelzi(etanercept) in the EU, and Zarxio (filgrastim) in the US.
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...